Compare Moody's Corporation (MCO) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Moody's Corporation trades at $462.77 (market cap $80.38B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Moody's Corporation is far larger — about 10.7× Spyre Therapeutics Inc. Common Stock's market cap, and Moody's Corporation pays a 0.89% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MCO | SYRE | |
|---|---|---|
Market Cap | $80.38B | $7.52B |
Volume | 628,586 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $539.61 | $108.92 |
52-Week Low | $412.23 | $22.18 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.40B | $6.52B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $462.77, down 1.64% on the day, as the stock consolidates near key support. The company maintains strong fundamentals with revenue reaching $7.72B in 2025 and net income margin expanding to 34.25%. Recent earnings beats and a bullish technical signal underscore positive momentum, while analyst consensus remains favorable with a $536.40 price target. Strategic moves like the PhilRatings stake and Google Cloud partnership highlight growth initiatives in the Asia-Pacific region and financial services technology.
Outlook: Moody's exhibits robust profitability and strategic expansion, supporting a positive investment case. Risks include high valuation multiples (P/E 29.45) and sensitivity to credit cycle fluctuations. The stock offers growth potential but requires monitoring of debt levels and macroeconomic trends affecting its credit rating business.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
